|Day Low/High||6.08 / 6.26|
|52 Wk Low/High||2.80 / 6.45|
Investors in BioDelivery Sciences International Inc saw new options become available this week, for the June 2020 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Major Pharmacy Benefit Manager (PBM) Improves Access for Both Products to Approximately 14 Million Lives Symproic Will be Listed as Preferred Exclusive and BELBUCA Preferred or Preferred Exclusive RALEIGH, N.
In trading on Friday, shares of BioDelivery Sciences International Inc crossed below their 200 day moving average of $4.41, changing hands as low as $4.30 per share. BioDelivery Sciences International Inc shares are currently trading down about 3.8% on the day.
BioDelivery Sciences International, Chiasma Inc. and TherapeticsMD all feature promising treatments.
New Scientific Information Further Highlights Clinical Profiles of BELBUCA® and Symproic®
In trading on Friday, shares of BioDelivery Sciences International Inc crossed above their 200 day moving average of $4.28, changing hands as high as $4.40 per share. BioDelivery Sciences International Inc shares are currently trading up about 6.7% on the day.
BELBUCA® Net Sales Increased 147% versus Prior Year to All-Time High of $24.1 Million Raises Full-Year BELBUCA Net Sales Expectations to $90 - $93 Million Raises Full-Year Total Company Net Sales Expectations to $101 - $105 Million Raises Long-Term...
NEW YORK, July 29, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of BioDelivery...
The trio consists of BioDelivery Sciences International, Beazer Homes USA and Redhill Biopharma.
Regional Commercial Plans Improved Access for More Than 6 Million Lives During 2Q More Than 90% of Commercial Lives Now Have Access to BELBUCA in the U.
Both Digital Turbine and BioDelivery Sciences have done well in 2019.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
I am incrementally using buy-write option orders to add some shares to core holdings.
Here are updates on small biotech/biopharma names I have profiled before.
Investors in BioDelivery Sciences International Inc saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BDSI options chain for the new May 17th contracts and identified one put and one call contract of particular interest.
Let's look at a couple of companies we have covered on these pages before.
One already is up nicely on its results, while the other two should issue reports of interest in the next few days.
We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.
Portola Pharmaceuticals, Flexion Therapeutics and BioDelivery Sciences delivered nice third-quarter numbers.
BioDelivery Sciences, Neos Therapeutics and Invitae Corp. are delivering big increases in sales.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.